A New Way To Hit Pancreatic Cancer’s Hardest Target

A first-in-class nanoparticle injection shows the power to shrink pancreatic tumors in mice by sneaking antibodies directly into cancer cells, clearing the notoriously untouchable mutant KRAS protein. Researchers have developed a tiny lipid nanoparticle that carries antibodies targeting the KRAS G12D mutation, a driver of most pancreatic cancers, and delivered them inside cancer cells with stunning precision, sparing healthy tissue entirely. The study, published alongside the Forbes report, demonstrates that a single intravenous injection reduced tumor volume by up to 60% in mouse models, with no significant toxicity to the liver, kidneys, or immune system. The breakthrough hinges on a clever delivery mechanism: the nanoparticle is coated with a peptide that binds specifically to a receptor overexpressed on pancreatic cancer cells, allowing the antibody payload to be endocytosed and released directly into the cytoplasm. Once inside, the antibody binds to mutant KRAS, blocking its oncogenic signaling pathways and triggering cell death. This approach overcomes the longstanding challenge of drugging KRAS, a protein that has been called 'undruggable' for decades because its smooth surface lacks obvious pockets for small molecules. While existing KRAS inhibitors like sotorasib and adagrasib have shown promise in lung cancer, they are less effective in pancreatic cancer due to poor tumor penetration and rapid drug resistance. The nanoparticle method bypasses those problems by using the body's own cellular machinery to deliver the blocker. The team, led by Dr. William Haseltine at the Innovation Lab (affiliated with the University of California), also engineered the antibody to be pH-sensitive, so it releases the KRAS-targeting fragment only inside the acidic environment of cancer cells. That design prevents off-target binding to normal cells, which express low levels of KRAS but lack the acidic endosomes. The results are a proof-of-concept that could accelerate into human trials within two years, pending FDA approval. However, experts caution that mouse models do not always predict human outcomes, especially for pancreatic cancer, which has a dense stroma that shields tumors. The next steps will involve testing in larger animal models and optimizing the nanoparticle's stability for human bloodstream conditions. If successful, this treatment could change the standard of care for the most lethal form of pancreatic cancer, which kills 90% of patients within five years. The nanoparticle platform is also adaptable to other KRAS mutations and even to other solid tumors by swapping the targeting peptide and antibody payload. For now, the cancer research community is watching closely: a new way to hit pancreatic cancer's hardest target may finally be within reach.